Abstract

Deactivation of an implantable cardioverter-defibrillator (ICD) is a critical issue in the advance care planning (ACP) of ICD recipients; however, related perspectives have rarely been explored. Thus, this study aimed to provide an initial investigation of ICD recipients’ perceived susceptibility and barriers/benefits regarding ACP and/or advance directives (ADs), and associations of these modifiable factors with preferences for end-of-life life-sustaining treatments (LSTs) (cardiopulmonary resuscitation (CPR), ventilator support, hemodialysis, and hospice care). Using a descriptive correlational design, 48 ICD recipients (age, 50.1 years; male, 85.4%) completed survey questionnaires. “No burden on family” was the most highly valued (59.1%), followed by “comfortable death” (20.4%), and both (11.4%). LST preference was 43.8% for ventilator support, 45.8% for both hemodialysis and hospice care, and 54.2% for CPR. Perceived susceptibility to having unexpected end-of-life experiences increased the likelihood of preference for aggressive LSTs, with preferences increasing by 15% for CPR, 17% for ventilator support, and 23% for hemodialysis. A non-modifiable factor, older age, was the only predictor of increased preference for hospice care (odds ratio = 1.09, p = 0.016). Among the modifiable factors, a higher perceived susceptibility increased the likelihood of aggressive LST preferences. The findings imply that to facilitate informed decisions for LSTs, early ACP discussion could be helpful and enhance these modifiable factors.

Highlights

  • The survival benefit of an implantable cardioverter-defibrillator (ICD) has been proven, and it is widely used as a standard procedure today [1] for either primary or secondary prevention for sudden cardiac arrest [2,3,4]

  • 60,000 Americans have received ICD therapy [5], and 105,000 Europeans have received ICDs [6], either alone or in a hybrid form with biventricular pacing, which is increasingly being used for patients with advanced heart failure— those undergoing ischemic cardiomyopathy who are at high risk of life-threatening arrhythmias [7]

  • Functional limitation measured by the New York Heart Association (NYHA)

Read more

Summary

Introduction

The survival benefit of an implantable cardioverter-defibrillator (ICD) has been proven, and it is widely used as a standard procedure today [1] for either primary or secondary prevention for sudden cardiac arrest [2,3,4]. Public Health 2020, 17, 4257; doi:10.3390/ijerph17124257 www.mdpi.com/journal/ijerph

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.